litlas
Log inCreate account

Garth Powis

Active 1980–2023

111
Papers
20,583
Citations
86
h-index
111
i10-index

Citations

Citations per year for Garth Powis1951: 1 citations1981: 2 citations1982: 6 citations1983: 3 citations1984: 7 citations1985: 7 citations1986: 7 citations1987: 13 citations1988: 13 citations1989: 23 citations1990: 43 citations1991: 40 citations1992: 37 citations1993: 35 citations1994: 36 citations1995: 63 citations1996: 66 citations1997: 73 citations1998: 110 citations1999: 138 citations2000: 173 citations2001: 158 citations2002: 136 citations2003: 196 citations2004: 202 citations2005: 263 citations2006: 230 citations2007: 211 citations2008: 204 citations2009: 271 citations2010: 235 citations2011: 202 citations2012: 242 citations2013: 169 citations2014: 208 citations2015: 191 citations2016: 169 citations2017: 178 citations2018: 143 citations2019: 520 citations2020: 497 citations2021: 451 citations2022: 380 citations2023: 238 citations2024: 339 citations2025: 153 citations2026: 1 citations1952–1980: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,357 citing papers, 32% of this breakdownChina: 820 citing papers, 11.2% of this breakdownUnited Kingdom: 428 citing papers, 5.8% of this breakdownGermany: 376 citing papers, 5.1% of this breakdownItaly: 312 citing papers, 4.2% of this breakdownJapan: 251 citing papers, 3.4% of this breakdownFrance: 239 citing papers, 3.3% of this breakdownCanada: 200 citing papers, 2.7% of this breakdownSweden: 185 citing papers, 2.5% of this breakdownSpain: 180 citing papers, 2.5% of this breakdownAustralia: 162 citing papers, 2.2% of this breakdownSouth Korea: 155 citing papers, 2.1% of this breakdown
0%32%Other 23%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology53.4%
  • Medicine29.2%
  • Nursing3.6%
  • Pharmacology, Toxicology and Pharmaceutics2.6%
  • Immunology and Microbiology2.4%
  • Chemistry2.4%
  • Other6.4%

Topics

  • Cancer, Hypoxia, and Metabolism5.1%
  • Redox biology and oxidative stress5%
  • PI3K/AKT/mTOR signaling in cancer2.7%
  • Glutathione Transferases and Polymorphisms2.5%
  • Genomics, phytochemicals, and oxidative stress2%
  • Sulfur Compounds in Biology1.6%
  • Other81.1%

Coauthors

All papers

Open in search
  1. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer

    Authors: Scott Kopetz, Jayesh Desai, Emily Chan, J. Randolph Hecht, Peter J. O’Dwyer, Dipen M. Maru, Van K. Morris, Filip Jankú, Arvind Dasari, Woonbok Chung, Jean‐Pierre J. Issa, Peter Gibbs, Brian P. James, Garth Powis, K. B. Nolop, Suman Bhattacharya, Leonard B. Saltz - Journal of Clinical Oncology 2015 cited by 693

  2. Passing the baton: the HIF switch

    Authors: Mei Yee Koh, Garth Powis - Trends in Biochemical Sciences 2012 cited by 585

  3. Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

    Authors: Nathan T. Ihle, Lauren A. Byers, Edward S. Kim, Pierre Saintigny, J. Jack Lee, George R. Blumenschein, Anne S. Tsao, Suyu Liu, Jill E. Larsen, Jing Wang, Lixia Diao, Kevin R. Coombes, Lu Chen, Shuxing Zhang, Mena Abdelmelek, Ximing Tang, Vassiliki A. Papadimitrakopoulou, John D. Minna, Scott M. Lippman, Waun Ki Hong, Roy S. Herbst, Ignacio I. Wistuba, John V. Heymach, Garth Powis - JNCI Journal of the National Cancer Institute 2012 cited by 529

  4. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α

    Authors: Mei Yee Koh, Taly R. Spivak-Kroizman, Sara Venturini, Sarah J. Welsh, Ryan Williams, D. Lynn Kirkpatrick, Garth Powis - Molecular Cancer Therapeutics 2008 cited by 305

  5. Thioredoxin reductase.

    Authors: Debbie J. Mustacich, Garth Powis - Biochemical Journal 2000 cited by 584

  6. The Hypoxia-Associated Factor Switches Cells from HIF-1α- to HIF-2α-Dependent Signaling Promoting Stem Cell Characteristics, Aggressive Tumor Growth and Invasion

    Authors: Mei Yee Koh, Robert Lemos, Xiuping Liu, Garth Powis - Cancer Research 2011 cited by 351

  7. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α

    Authors: Sarah J. Welsh, Ryan Williams, Lynn Kirkpatrick, Gillian Paine-Murrieta, Garth Powis - Molecular Cancer Therapeutics 2004 cited by 245

  8. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase.

    Authors: Garth Powis, Rosanne Bonjouklian, Margareta Berggren, Alfred Gallegos, Robert T. Abraham, Curtis L. Ashendel, Leon H. Zalkow, William F. Matter, Jeffrey A. Dodge, Gerald B. Grindey - 1994 cited by 691

  9. Fluorescent probes towards selective cathepsin B detection and visualization in cancer cells and patient samples

    Authors: Marcin Poręba, Katarzyna Groborz, Matej Vizovišek, Marco Maruggi, Dusan Turk, Boris Turk, Garth Powis, Marcin Drąg, Guy S. Salvesen - Chemical Science 2019 cited by 80

  10. Pleckstrin Homology [PH] domain, structure, mechanism, and contribution to human disease

    Authors: Garth Powis, Emmanuelle J. Meuillet, Martín Indarte, Garrett Booher, Lynn Kirkpatrick - Biomedicine & Pharmacotherapy 2023 cited by 44

  11. Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents

    Authors: Muling Mao, Feng Tian, John M. Mariadason, Chun C. Tsao, Robert Lemos, Farshid Dayyani, Y.N. Vashisht Gopal, Zhi-Qin Jiang, Ignacio I. Wistuba, Xi Tang, William G. Bornman, Gideon Bollag, Gordon B. Mills, Garth Powis, Jayesh Desai, Gary E. Gallick, Michael A. Davies, Scott Kopetz - Clinical Cancer Research 2012 cited by 298

  12. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.

    Authors: Sarah J. Welsh, Ryan Williams, Lynn Kirkpatrick, Gillian Paine-Murrieta, Garth Powis - 2004 cited by 281

  13. Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice

    Authors: Jörg J. Jacoby, Baruch Erez, Maria Korshunova, Ryan Williams, Kazuhisa Furutani, Osamu Takahashi, Lynn Kirkpatrick, Scott M. Lippman, Garth Powis, Michael S. O’Reilly, Roy S. Herbst - Journal of Thoracic Oncology 2010 cited by 84

  14. Crystal structures of reduced, oxidized, and mutated human thioredoxins: evidence for a regulatory homodimer

    Authors: A. Weichsel, John R. Gasdaska, Garth Powis, W.R. Montfort - Structure 1996 cited by 380

  15. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma

    Authors: Dimpy Koul, Ruoqi Shen, Young‐Woo Kim, Yutaka Kondo, Yue Lu, James A. Bankson, Sabrina M. Ronen, David Kirkpatrick, Garth Powis, W. K. Alfred Yung - Neuro-Oncology 2010 cited by 129

  16. Efficacy of the combination of MEK and CDK4/6 inhibitorsin vitroandin vivoin KRAS mutant colorectal cancer models

    Authors: Michael S. Lee, Timothy L. Helms, Ningping Feng, Jason Gay, Qing Chang, Feng Tian, Ji Yuan Wu, Carlo Toniatti, Timothy P. Heffernan, Garth Powis, Lawrence N. Kwong, Scott Kopetz - Oncotarget 2016 cited by 126

  17. HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer

    Authors: Hae Ryung Chang, Seungyoon Nam, Myeong‐Cherl Kook, Kyung-Tae Kim, Xiuping Liu, Hui Yao, Hae Rim Jung, Robert Lemos, Hye Hyun Seo, Hee Seo Park, Youme Gim, Dongwan Hong, Iksoo Huh, Young‐Woo Kim, Young‐Woo Kim, Dongfeng Tan, Chang‐Gong Liu, Garth Powis, Taesung Park, Han Liang, Yon Hui Kim, Yon Hui Kim - Gut 2014 cited by 119

  18. FXR silencing in human colon cancer by DNA methylation and KRAS signaling

    Authors: Ann M. Bailey, Le Zhan, Dipen M. Maru, Imad Shureiqi, Curtis R. Pickering, Galina M. Kiriakova, Julie Izzo, Nan He, Caimiao Wei, Veerabhadran Baladandayuthapani, Han Liang, Scott Kopetz, Garth Powis, Grace L. Guo - American Journal of Physiology-Gastrointestinal and Liver Physiology 2013 cited by 85

  19. Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1α Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target

    Authors: Geoffrey Grandjean, Petrus R. de Jong, Brian P. James, Mei Yee Koh, Robert Lemos, John Kingston, Alexander E. Aleshin, Laurie A. Bankston, Claudia P. Miller, Eun Jeong Cho, Ramakrishna Edupuganti, Ashwini K. Devkota, Gabriel Stancu, Robert Liddington, Kevin N. Dalby, Garth Powis - Cancer Research 2016 cited by 81

  20. The Absence of Mitochondrial Thioredoxin 2 Causes Massive Apoptosis, Exencephaly, and Early Embryonic Lethality in Homozygous Mice

    Authors: Larisa Nonn, Ryan Williams, Robert P. Erickson, Garth Powis - Molecular and Cellular Biology 2003 cited by 439

  21. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

    Authors: Nathan T. Ihle, Ryan Williams, Sherry Chow, Wade M. Chew, Margareta Berggren, Gillian Paine-Murrieta, Daniel J. Minion, Robert J. Halter, Peter Wipf, Robert T. Abraham, Lynn Kirkpatrick, Garth Powis - Molecular Cancer Therapeutics 2004 cited by 312

  22. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival

    Authors: Jennifer Raffel, A. K. Bhattacharyya, Alfred Gallegos, Haiyan Cui, Janine G. Einspahr, David S. Alberts, Garth Powis - Journal of Laboratory and Clinical Medicine 2003 cited by 219

  23. Hypoxia Triggers Hedgehog-Mediated Tumor–Stromal Interactions in Pancreatic Cancer

    Authors: Taly R. Spivak-Kroizman, Galen Hostetter, Richard G. Posner, Meraj Aziz, Chengcheng Hu, Michael J. Demeure, Daniel D. Von Hoff, Sunil R. Hingorani, Timothy Blake Palculict, Julie Izzo, Galina M. Kiriakova, Mena Abdelmelek, Geoffrey Bartholomeusz, Brian P. James, Garth Powis - Cancer Research 2013 cited by 209

  24. Hypoxia-Associated Factor, a Novel E3-Ubiquitin Ligase, Binds and Ubiquitinates Hypoxia-Inducible Factor 1α, Leading to Its Oxygen-Independent Degradation

    Authors: Mei Yee Koh, Bryant G. Darnay, Garth Powis - Molecular and Cellular Biology 2008 cited by 176